B Cell Lymphoma
News
Entospletinib falls short in relapsed/refractory DLBCL
The oral, selective inhibitor of spleen tyrosine kinase had a high rate of adverse events and treatment interruption in the phase 2 study.
Conference Coverage
MCL treatment choices depend partly on age
CHICAGO – There are important treatment differences in patients aged 65 and younger versus those over 65.
News
Phase 1 NHL, ALL trials placed on clinical hold
Update: On October 12, 2018, Affimed N.V. received a notification from the U.S. Food and Drug Administration (FDA) saying the agency concurred...
Conference Coverage
ALTA-1L: Brigatinib beats crizotinib for PFS in ALK-positive NSCLC
The ALTA-1L trial showed a 51% reduction in progression-free survival with brigatinib versus crizotinib in ALK-positive NSCLC.
News
Weighing the costs of CAR T-cell therapy
The cost-effectiveness of tisagenlecleucel (Kymriah) depends on long-term clinical outcomes, which are presently unknown, according to...
News
CAR T therapy being explored in Hodgkin lymphoma
New York—Although the data set is small and not yet mature, chimeric antigen receptor (CAR) T-cell therapy appears to be a promising approach for...
News
Duvelisib bests ofatumumab as monotherapy for treatment of CLL/SLL
Final analysis of the phase 3 DUO trial has shown monotherapy with oral duvelisib results in a statistically significant improvement in...
News
5-year remission rates with combo prove durable in MCL
Long-term results of a phase 2 clinical trial of the lenalidomide and rituximab combination as first-line therapy for mantle cell lymphoma (MCL)...
Conference Coverage
Novel options for treating hairy cell leukemia
NEW YORK –
News
Ground-breaking therapy comes with distinct challenges
NEW YORK—Two chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel (Yescarta ®) and tisagenlecleucel (Kymriah™)—are already...